+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pain Management Therapeutics Market - Global Forecast 2026-2032- Product Image
Pain Management Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Pain Management Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896709
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pain Management Therapeutics Market is projected to reach USD 93.78 Billion in 2026. It is expected to continue growing at a CAGR of 5.00%, reaching USD 126.75 Billion by 2032.

Pain management therapeutics are being reshaped by the global burden of chronic pain, aging populations, rising musculoskeletal disorders, cancer-related pain, postsurgical pain, neuropathic pain, and migraine. Verified public-health evidence underscores the scale: the U.S. CDC reported that 20.9% of U.S. adults experienced chronic pain in 2021, while the WHO and IASP recognize pain as a major driver of disability, reduced quality of life, and reduced functional capacity.

The market is moving beyond conventional opioid-centered care toward multimodal pain management, including nonsteroidal anti-inflammatory drugs, acetaminophen, anticonvulsants, antidepressants, topical analgesics, local anesthetics, biologics, neuromodulation-adjacent therapeutics, and digital pain support tools. Commercial success increasingly depends on demonstrating measurable outcomes, safety, real-world effectiveness, and alignment with opioid stewardship policies.

Transformative Shifts in the Pain Therapeutics Landscape

The pain management therapeutics landscape is undergoing a structural shift from symptom suppression to precision, evidence-led, and patient-specific treatment pathways. Regulators, payers, and clinicians are prioritizing non-opioid analgesics, abuse-deterrent formulations, safer prescribing protocols, and therapies that address neuropathic, inflammatory, nociplastic, and mixed pain mechanisms.

Scientific progress is also changing competitive positioning. CGRP-targeted migraine therapies, sodium-channel research, cannabinoid-based programs where permitted, extended-release local anesthetics, and repurposed neuromodulatory medicines are expanding the innovation pipeline. At the same time, formulary access is increasingly tied to comparative effectiveness, pharmacovigilance, and health-economic evidence rather than brand recognition alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across pain therapeutic discovery, clinical development, prescribing support, and patient monitoring. AI-enabled target identification, molecular screening, trial feasibility analytics, and real-world evidence mining can reduce uncertainty in identifying pain phenotypes and treatment-response patterns.

In clinical and commercial use, AI supports risk stratification for opioid misuse, adverse-event detection, dose optimization, and remote symptom tracking through digital health platforms. The impact is not a single disruption but an accumulating advantage: organizations that combine compliant data governance, validated algorithms, and clinician oversight can improve trial design, personalize therapy selection, and strengthen payer evidence packages.

Key Regional Insights for Pain Management Therapeutics

Asia-Pacific is becoming a high-priority arena for pain management therapeutics due to population scale, rapid aging in Japan, China, South Korea, and Australia, and expanding access to specialty care in India and Southeast Asia. Demand is supported by osteoarthritis, low back pain, diabetic neuropathy, migraine, cancer pain, and postsurgical pain, while affordability, reimbursement diversity, and local prescribing pathways continue to shape product uptake.

North America remains the most evidence-intensive and policy-sensitive region, led by the United States and Canada. The region combines high chronic pain prevalence, advanced specialty prescribing, strong adoption of migraine and biologic therapies, and rigorous opioid-risk controls. Latin America, led by Brazil and Mexico, is expanding access through public and private channels, though budget constraints, fragmented reimbursement, and uneven specialist availability influence adoption.

Europe is shaped by aging demographics, strong health technology assessment requirements, and country-specific reimbursement pathways across Germany, France, Italy, Spain, and the United Kingdom. The Middle East, particularly GCC health systems, is investing in hospital capacity, oncology care, and specialty clinics, supporting higher-value pain therapies with clear clinical evidence. Africa remains access-constrained but shows sustained need for affordable analgesics, palliative care medicines, essential pain education, and stronger supply continuity.

Key Economic and Strategic Group Insights

ASEAN markets show rising demand for affordable pain medicines, diabetic neuropathy treatment, migraine care, and postoperative pain control as healthcare coverage expands and chronic disease prevalence grows. Commercial strategies in the region require differentiated pricing, local partnerships, and education-led adoption because reimbursement, pharmacy access, and prescribing infrastructure differ widely among member states.

The GCC is increasingly aligned with specialty-care modernization, oncology investment, and hospital-based pain services, making it attractive for premium therapeutics with strong clinical evidence and safety profiles. The European Union is defined by regulatory harmonization through centralized and national procedures but commercial fragmentation through national HTA and reimbursement systems, requiring country-level evidence planning and early payer engagement.

BRICS countries represent large-volume access opportunities, with China, India, and Brazil offering population scale and Russia and South Africa contributing distinct affordability, procurement, and access dynamics. G7 markets remain the benchmark for innovation uptake, pharmacovigilance, controlled-substance oversight, and payer scrutiny. NATO countries overlap heavily with advanced European and North American systems, where supply security, controlled-medicine governance, and resilient pharmaceutical logistics are strategic priorities for pain management therapeutics.

Key Country Insights Across Priority Markets

The United States is the central market for pain management therapeutics due to high chronic pain prevalence, advanced specialist care, extensive clinical research activity, and strong regulatory attention to opioid stewardship. Canada follows similar safety priorities while emphasizing public reimbursement and evidence-based prescribing. Mexico and Brazil offer expanding access opportunities across branded generics, anti-inflammatory drugs, neuropathic pain medicines, migraine therapies, and hospital-based pain management.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national health systems, HTA standards, and aging populations with a high musculoskeletal pain burden. Germany remains important for early European launch strategy, while France, Italy, and Spain require strong reimbursement dossiers and comparative clinical evidence. Russia presents demand for affordable and locally accessible pain therapies amid a complex regulatory, procurement, and operating environment.

China and India are major long-term priority markets because of population scale, diabetes-related neuropathy, cancer care expansion, musculoskeletal disease burden, and rising urban healthcare access. Japan has high demand associated with aging, osteoarthritis, neuropathic pain, postsurgical pain, and migraine management. Australia and South Korea offer sophisticated regulatory systems, high digital-health readiness, and opportunities for evidence-backed specialty therapies supported by real-world outcomes and clinician education.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated non-opioid and opioid-sparing portfolios supported by robust clinical endpoints, real-world evidence, and safety data. Development programs should segment patients by pain mechanism, comorbidities, functional impairment, and treatment history to improve trial success and payer relevance.

Organizations should invest in AI-enabled evidence generation, pharmacovigilance, and patient-reported outcome platforms while maintaining transparent governance and regulatory validation. Market access teams need region-specific reimbursement strategies, education programs for clinicians, and partnerships with health systems to support responsible prescribing, adherence, and measurable functional outcomes.

Research Methodology

The executive summary is based on structured secondary research and evidence triangulation using authoritative sources such as WHO, CDC, NIH, FDA, EMA, OECD health data, national health agencies, peer-reviewed journals, clinical trial registries, and public regulatory guidance. Insights were evaluated for relevance to therapeutic classes, disease burden, prescribing behavior, reimbursement, safety monitoring, and regional access conditions.

The methodology emphasizes verified public-health indicators, regulatory trends, clinical evidence, and commercially observable market dynamics. Qualitative interpretation was applied to identify strategic implications while avoiding unsupported market-size claims, market share estimates, or unverified projections.

Conclusion

Pain management therapeutics are entering a new phase defined by safety, personalization, non-opioid innovation, and evidence-based access. The market remains essential because chronic and acute pain continue to impose substantial clinical, economic, and social burden across developed and emerging healthcare systems.

Organizations that combine scientifically differentiated therapies, responsible opioid stewardship, AI-supported evidence generation, and region-specific commercialization will be best positioned to achieve sustainable competitiveness. The next advantage will come from proving not only analgesic efficacy but also functional improvement, safety, adherence, patient experience, and value for payers and patients.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pain Management Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Adjuvant Analgesics
7.3. Local Anesthetics
7.4. Neuropathic Pain Agents
7.4.1. Anticonvulsants
7.4.2. Antidepressants
7.5. Nonsteroidal Anti-Inflammatory Drugs
7.5.1. Cox-2 Inhibitors
7.5.2. Traditional NSAIDs
7.6. Opioids
7.6.1. Strong Opioids
7.6.2. Weak Opioids
8. Pain Management Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.3.1. Intramuscular
8.3.2. Intravenous
8.3.3. Subcutaneous
8.4. Topical
8.5. Transdermal
9. Pain Management Therapeutics Market, by Indication
9.1. Introduction
9.2. Acute Pain
9.3. Chronic Pain
9.3.1. Low Back Pain
9.3.2. Neuropathic Chronic Pain
9.3.3. Osteoarthritis
9.3.4. Rheumatoid Arthritis
9.4. Inflammatory Pain
9.5. Neuropathic Pain
10. Pain Management Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Pain Management Therapeutics Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care Settings
11.3.1. Hospice Care
11.3.2. Patient Home
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Pain Management Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Pain Management Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Pain Management Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. Amgen Inc.
16.4. Assertio Holdings, Inc.
16.5. AstraZeneca plc
16.6. Aurobindo Pharma Limited
16.7. Bayer AG
16.8. Boston Scientific Corporation
16.9. Cipla Limited
16.10. Daiichi Sankyo Company, Limited
16.11. Dr. Reddy’s Laboratories Limited
16.12. Eli Lilly and Company
16.13. Endo International plc
16.14. Fresenius Kabi AG
16.15. GlaxoSmithKline plc
16.16. Grünenthal GmbH
16.17. Hikma Pharmaceuticals PLC
16.18. Johnson & Johnson Services, Inc.
16.19. Kyowa Kirin Co., Ltd.
16.20. Lupin Limited
16.21. Mallinckrodt plc
16.22. Merck & Co., Inc.
16.23. Novartis AG
16.24. Pfizer Inc.
16.25. Purdue Pharma L.P.
16.26. Sanofi S.A.
16.27. Sun Pharmaceutical Industries Ltd.
16.28. Takeda Pharmaceutical Company Limited
16.29. Teva Pharmaceutical Industries Ltd.
16.30. Vertex Pharmaceuticals Incorporated
16.31. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL STRONG OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL STRONG OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL STRONG OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL WEAK OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL WEAK OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL WEAK OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ACUTE PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ACUTE PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ACUTE PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CHRONIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CHRONIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LOW BACK PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LOW BACK PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LOW BACK PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPICE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPICE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPICE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PATIENT HOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PATIENT HOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PATIENT HOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 153. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 158. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 159. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 160. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 161. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 162. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 165. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 179. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 181. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 182. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 183. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 184. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 186. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 187. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 188. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 191. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 195. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 196. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 197. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 198. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 200. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 201. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 202. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 205. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 206. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 209. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 210. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 211. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 213. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 214. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 215. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 218. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 232. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 235. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 236. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 237. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 239. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 240. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 241. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 244. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 245. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 248. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 249. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 250. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 252. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 253. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 254. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 257. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 258. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 261. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 262. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 263. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 265. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 266. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 267. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 270. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 271. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 285. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 287. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 288. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 289. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 290. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 292. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 293. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 294. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 297. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 298. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 301. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 302. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 303. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 305. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 306. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 307. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 310. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 323. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD M

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Assertio Holdings, Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boston Scientific Corporation
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Grünenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 93.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 126.75 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Cancer Pain Management Market - Global Forecast 2026-2032 - Product Image

Cancer Pain Management Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Chronic Post-Amputation Pain Management Market - Global Forecast 2026-2032 - Product Image

Chronic Post-Amputation Pain Management Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Non-opioid Pain Patch - Global Strategic Business Report - Product Image

Non-opioid Pain Patch - Global Strategic Business Report

  • Report
  • 483 Pages
  • Global
From
Gabapentin - Global Strategic Business Report - Product Image

Gabapentin - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034 - Product Image

Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034

  • Report
  • 142 Pages
  • Global
From

About the Pain Management Market

The Pain Management market within the context of Analgesics is a large and diverse field. It includes a variety of products and services designed to reduce or eliminate pain. These products and services range from over-the-counter medications to prescription drugs, physical therapy, and alternative treatments. Analgesics are a type of medication used to reduce or eliminate pain. They can be divided into two main categories: non-opioid analgesics, such as ibuprofen and acetaminophen, and opioid analgesics, such as morphine and oxycodone. Non-opioid analgesics are generally considered to be safer and more effective than opioid analgesics, but they are not as effective at treating severe pain. The Pain Management market is highly competitive, with many companies offering a variety of products and services. Some of the major players in the market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Merck, Novartis, and Eli Lilly. Other companies in the market include Teva Pharmaceuticals, Mylan, and Endo Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.